Fusion Pharmaceuticals Inc.

Targeted Alpha Therapeutics for chemo-resistant Cancers

https://fusionpharma.com/fusion-pipeline/

Fusion Pharmaceuticals is developing next-generation radiopharmaceuticals as an alternative cancer therapy. Alpha particles are a type of ionizing radiation that induces DNA damage and can be used to kill cells. Fusion arms targeting molecules, like antibodies, with potent alpha emitting medical isotopes to precisely and effectively induce cancer cell death. Alpha particles are useful here since they only travel a short distance, localizing the radiation to the tumor. However, Fusion is also using their proprietary Fast-ClearTM linker technology to promote the rapid clearance of medical isotopes not specifically bound to cancer to create safer therapeutics. Fusion is leveraging their technology to advance a pipeline of alpha-based therapeutic programs to treat various cancers.